Skip to main content
. Author manuscript; available in PMC: 2015 Dec 1.
Published in final edited form as: Eur J Cancer. 2013 May 28;49(13):2841–2850. doi: 10.1016/j.ejca.2013.04.019

Fig. 4.

Fig. 4

Individual and mean (shown in bold) tivozanib (1.5 mg) serum concentration versus time by dose level throughout cycle 1. Although substantial individual variation was observed, there was a clear relationship between tivozanib concentration and dose, and an accumulation of tivozanib to nearly steady-state levels over the 21-d treatment period.